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AbsTrACT
Introduction Artemether- lumefantrine (AL) is the most 
widely- recommended treatment for uncomplicated 
Plasmodium falciparum malaria. Its efficacy has 
been extensively assessed in clinical trials. In routine 
healthcare settings, however, its effectiveness can be 
diminished by delayed access to treatment and poor 
adherence. As well as affecting clinical outcomes, these 
factors can lead to increased transmission, which is the 
focus of this study.
Methods We extend a within- host model of P. 
falciparum to include gametocytes, the parasite forms 
responsible for onward transmission. The model includes 
a pharmacokinetic–pharmacodynamic model of AL, 
calibrated against both immature and mature gametocytes 
using individual- level patient data, to estimate the impact 
that delayed access and imperfect adherence to treatment 
can have on onward transmission of the parasite to 
mosquitoes.
results Using survey data from seven African countries 
to determine the time taken to acquire antimalarials 
following fever increased our estimates of mean total 
infectivity of a malaria episode by up to 1.5- fold, compared 
with patients treated after 24 hours. Realistic adherence 
behaviour, based on data from a monitored cohort in 
Tanzania, increased the contribution to transmission 
by 2.2 to 2.4- fold, compared with a perfectly- adherent 
cohort. This was driven largely by increased rates of 
treatment failure leading to chronic infection, rather than 
prolonged gametocytaemia in patients who have slower, 
but still successful, clearance of parasites after imperfect 
adherence to treatment. Our model estimated that the 
mean infectivity of untreated infections was 29–51 times 
higher than that of treated infections (assuming perfect 
drug adherence), underlining the importance of improving 
treatment coverage.
Conclusion Using mathematical modelling, we quantify 
how delayed treatment and non- adherent treatment can 
increase transmission compared with prompt effective 
treatment. We also highlight that transmission from 
the large proportion of infections which never receive 
treatment is substantially higher than those treated.
InTroduCTIon
Although significant declines in malaria prev-
alence have been achieved this century, recent 
evidence suggests that progress in reducing 
the burden of disease has stalled. In 2017 
there were an estimated 219 million cases of 
Key questions
What is already known?
 ► Artemether- lumefantrine (AL), the most widely- 
recommended treated for uncomplicated 
Plasmodium falciparum worldwide, has been proven 
in clinical trials to be efficacious and well- tolerated.
 ► In routine healthcare settings treatment efficacy can 
be diminished by delayed access to drugs, or imper-
fect adherence to the dosing regimen, although this 
effect is difficult to quantify.
What are the new findings?
 ► Using individual- level adherence data collected in 
Tanzania as input to our within- host model of a ma-
laria infection treated with AL, we find that the on-
ward transmission from a treated cohort of patients 
is more than double that of a perfectly- adherent 
cohort.
 ► In our model delayed access to treatment, de-
termined from data on the time taken to acquire 
antimalarials following fever in malaria- endemic 
countries, increased onward transmission by up to 
50%, compared with patients treated 24 hours after 
becoming febrile.
What do the new findings imply?
 ► We underline the importance of good adherence 
and prompt access to treatment, by showing how 
they can reduce onward transmission of the malaria 
parasite.
 ► Our modelling framework also allows us to compare 
the transmission capacity of treated patients with 
the much greater contribution to transmission made 
by untreated patients, emphasising the importance 
of extending treatment coverage.
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malaria globally, compared with an estimated 217 million 
the year before.1 The key to bringing these numbers 
down is to increase access to vector control interventions, 
malaria diagnostic tools and quality- assured antimalarial 
treatment.2 Given the malaria parasite’s ability to develop 
resistance to antimalarial drugs,3 4 it is extremely impor-
tant to maximise the efficacy of existing therapies, as well 
as identify novel antimalarial molecules to diversify the 
frontline therapies available to treat clinical disease. A 
number of factors contribute to suboptimal use of existing 
drugs, such as poor quality medication (including coun-
terfeit medication), incorrect diagnosis of the cause of 
fever, a lack of access to WHO- recommended treatments, 
and poor adherence to the recommended treatment 
regimens.5–10 It is important to quantify how these factors 
reduce the levels of effective coverage in malaria endemic 
settings, and how this affects disease burden.11 12
Artemisinin- combination therapies (ACTs) are the 
frontline treatments for uncomplicated cases of Plasmo-
dium falciparum, the human malaria species responsible 
for a large proportion of the global mortality. There 
are currently five WHO- approved ACTs available, all of 
which require a 3- day dosing regimen.13 The most widely- 
recommended ACT globally is artemether- lumefantrine 
(AL), which is the focus of our study. As of 2017, it is the 
first or second line treatment in 32 countries in Africa, 11 
in the Americas, five in the Eastern Mediterranean, six in 
South- East Asia and five in the Western Pacific.1
In previous work we developed a within- host model of 
uncomplicated P. falciparum malaria in order to obtain 
an estimate of the impact of imperfect adherence to AL 
on treatment outcomes.14 To do this we used data on the 
number of doses taken and their timings from an unsu-
pervised cohort in Tanzania collected in 2012.15 Our 
modelling work predicted a treatment failure rate of 4% 
if compliance was optimal (as in a clinical trial setting) 
but a higher failure rate of 9% if compliance was as 
observed. Of all the currently approved ACTs, AL has the 
most complex treatment regimen, requiring two doses 
per day instead of one, which may accentuate the diffi-
culties in achieving good adherence.
Although the primary goal of an ACT is to clear the 
asexual parasite population and, therefore, restore the 
patient to health, artemisinin- based drugs also have a 
partial killing effect against the sexual- stage parasites 
(gametocytes), clearing developing gametocytes and 
reducing the circulation time of mature gametocytes. 
Both a female and male gametocyte, in their mature 
forms,16 must be taken up by a feeding Anopheles mosquito 
in order for onward transmission to occur. Treatment 
with an ACT can therefore reduce the probability that 
the patient will contribute to transmission after treat-
ment. This is in contrast to other older treatments such 
as chloroquine and sulfadoxine- pyrimethamine, which 
have much weaker action against gametocytes.17 18
In P. falciparum, the delay between the appearance 
of asexual parasites and mature gametocytes in the 
peripheral blood is longer than in the other human 
malaria species.19 In a recent controlled infection study 
in malaria- naive human volunteers, it was measured to 
be 8.5–12 days.20 As artemisinin derivatives are highly 
effective against immature gametocytes,21 prompt treat-
ment with an ACT can reduce the parasite’s transmission 
capacity. Delaying treatment allows more time for sexual- 
stage parasites to accumulate and mature, making an 
infected human more infectious to a feeding mosquito. 
For example, in a cohort of Nigerian children, a duration 
of clinical symptoms of more than 3 days was found to be 
a risk factor for having microscopy- detectable gametocy-
taemia at the time of presentation at a treatment facility.22
To assess the extent to which transmission increases 
due to delays to treatment and imperfect adherence, 
here we have extended our within- host model of asexual 
parasitaemia14 to also include sexual- stage parasites. We 
first modelled gametocytaemia in an untreated infec-
tion, and calibrated this model using data collected from 
neurosyphilis patients, who were infected with P. falci-
parum parasites to treat their syphilis infections.23 We have 
extended an existing pharmacokinetic–pharmacody-
namic (PKPD) model for AL to quantify the effect on the 
sexual stage parasites, by fitting a PD model to individual- 
level clinical trial gametocyte density data following AL 
treatment. We estimated the probability that a mosquito 
would be successfully infected after taking a blood meal 
using a published model.24 We then combined these 
models with data on doses and timings collected from 
an unsupervised cohort in routine healthcare settings in 
Tanzania in 2012 to assess the contribution to transmis-
sion that stems from imperfect adherence; and we simi-
larly used household survey data from endemic settings 
on the time taken to seek treatment to assess the role 
that delaying treatment can have on transmission. We 
also compared treated patients’ transmission capacity 
with untreated infections to assess the importance of 
improving treatment coverage in reducing malaria trans-
mission at the population level.
MeTHods
Characterising the gametocyte dynamics
The modelling work developed for this analysis built 
on our previous published within- host model, which 
describes asexual parasite density over the course of an 
uncomplicated P. falciparum infection (details in Chal-
lenger et al14). In that work, we described the dynamics of 
an untreated infection, including the immune response 
mounted against the parasite, using the malaria therapy 
dataset23 to calibrate the model. We used an existing 
population- PK model of AL,25 along with clinical trial 
data on AL efficacy, to calibrate a PD model of AL 
against asexual parasites. The timing of drug treatment 
in the model was guided by data on the time required to 
obtain antimalarials following fever in endemic settings26 
and the observed pyrogenic thresholds of the malaria 
therapy patients.27 We here extended our investigation 
by including gametocyte production and characterising 
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the effect that the two drugs have against the sexual- 
stage parasites. The drug model has been calibrated 
to data collected under controlled conditions that is, 
with perfect drug adherence. In the Results section, we 
explore the impact of imperfect adherence to the treat-
ment regimen.
There are five morphologically- distinct gametocyte 
stages,28 which we label as  G1  (most immature) to  G5  
(mature). Experimental evidence suggests that commit-
ment to the sexual pathway is made at the schizont stage 
of the blood- stage cycle, placing all resulting merozoites 
on the gametocyte pathway.29 Immature gametocytes 
undergo sequestration, primarily in the bone marrow,30 
returning to the blood circulation in their mature forms 
( G5 ).
To characterise the relationship between a patient’s 
asexual and sexual parasitaemia, three factors need to 
be determined: the proportion of asexual parasites that 
commit to the sexual pathway, the length of time that 
gametocytes require to mature and the length of time 
that gametocytes (once mature) remain in the blood-
stream. Using the malaria therapy dataset, detailed 
modelling work has been carried out to scrutinise 
these quantities, comparing models with a range of 
complexity.31 32 In these studies, large inter- individual 
variation was observed. The authors demonstrated that 
allowing the commitment rate to vary for each wave 
of asexual parasitaemia (see online supplementary 
methods) improved the model fit, that is, the propor-
tion of parasites that develop into gametocytes can vary 
appreciably over the course of a single infection. Here 
we have built on these approaches, with several modifica-
tions. First, since our model of asexual parasitaemia has 
a time step of 48 hours, we generated gametocyte densi-
ties based on asexual parasitaemia data collected on odd 
days, instead of daily data. We explicitly modelled the 
sequestered parasite stages  
(
G1,G2,G3,G4
)
 , to capture 
AL’s effect on both immature and mature gametocytes. 
For simplicity we assumed that the gametocytes spend 
an equal amount of time in each of the four immature 
stages. In vitro experiments do report the duration of 
the immature stages,28 33–35 but these values vary between 
studies. Finally, we model the gametocyte dynamics in 
continuous time, to ease the combination with the PKPD 
model of AL. The model equations can be found in the 
online supplementary methods.
The malaria therapy dataset contains daily measure-
ments, stated as an integer number of parasites per µl, 
of both asexual and sexual parasitaemia for each patient, 
measured by microscopy.23 The full dataset contains infec-
tions from 334 patients: we fitted our model to a subset 
of 76, who did not receive any subcurative medication 
during the therapy and who were positive for gametocytes 
on at least 5 days. We use a patient’s asexual parasitaemia 
on odd days to predict that patient’s gametocytaemia, 
using a Poisson likelihood. The parameter combination 
that maximised the likelihood of the parameters for each 
patient was estimated using Markov Chain Monte Carlo 
methods. Further details can be found in the online 
supplementary methods.
Modelling the impact of drug treatment on the gametocyte 
population
To describe the drug concentrations observed following 
treatment with AL, we used a population- PK model due 
to Hodel et al.25 The PK model was fitted to data from 
both children and adults, patients were provided with 
food and mothers were encouraged to breastfeed infant 
patients, as lumefantrine (LMF) is better absorbed with 
some fat. We also used this model to calibrate a PD 
model for AL against asexual parasites.14 In that work, 
we quantified how imperfect adherence can increase the 
probability that treatment with AL fails to clear the infec-
tion. We illustrate this in online supplementary figure 1, 
where we show how missing doses reduces drug concen-
tration levels in the blood. Here we extended our PD 
model to include effects of AL against gametocytes. In 
order to reduce the parameter space, we assumed that 
artemether (AM) and its active metabolite dihydroar-
temisinin have identical antimalarial properties, and 
we ignored the effects of the active metabolite of LMF, 
desbutyl- lumefantrine, as its concentration is much lower 
than that of LMF. As stated previously,14 this means that 
the effect of the partner drug is only represented by 
the concentration of LMF. This may lead to the antima-
larial properties of LMF being overestimated, but we do 
not expect this effect to be large. We also assumed that 
the two drugs act independently. Although our model 
contains all five gametocyte stages, it is not feasible to 
differentiate between the drug effect on for example, 
stages  G1  and  G2  as, in vivo, we only observe the mature, 
circulating gametocyte population. Furthermore, it is 
not straightforward to tease apart the relative contribu-
tions to gametocyte killing from AM versus LMF. The PD 
model has the form.
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)
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AM,LMF
)
 
(1)
Here  kji   denotes the maximum killing rate of drug  j  
against gametocyte stage  i and  Cj50  is the concentration 
at which the killing rate of drug  j  is half of its maximum 
value. We used in vitro data to guide the model fitting,21 
specifically the relative strengths of gametocyte killing 
from AM versus LMF and the fact that the killing effects 
of both drugs are lower against more mature gameto-
cytes. To reduce the parameter space, certain parameters 
were fixed during the model fitting process (see online 
supplementary methods).
To quantify the drug effect on gametocytes, we used 
data by Goncalves et al,36 in which asymptomatic chil-
dren with patent gametocytaemia were treated with six 
doses of AL, quantifying gametocyte densities using 
quantitative reverse- transcriptase PCR. We compared our 
model output with gametocytaemia data for 42 patients, 
measured on day 0 (baseline), day 2, day 3 and day 7, 
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while varying the PD parameters in the model. Full details 
of the model fitting are given in the online supplemen-
tary methods: briefly, we introduced a distance metric to 
describe the difference between patient data and simu-
lated gametocytaemia in the model, as illustrated in 
online supplementary figure 2. We used likelihood- free 
inference methods37 to explore the PD parameter space.
Translating gametocyte density into infectivity
We estimated the probability that a feeding mosquito 
would be successfully infected by using a recent study 
by Bradley et al,24 which analysed data collected from 
gametocyte carriers in Mali, Burkina Faso and Came-
roon. The authors found that the best model for esti-
mating the probability that a feeding mosquito would 
become infected used information on both the male 
and female gametocyte populations, rather than only 
the total gametocyte density. The authors also estimated 
a density- dependent relationship between the male and 
female gametocyte densities in each infection, which 
shows a bias towards male gametocytes at low gameto-
cyte densities and a bias towards female gametocytes at 
higher densities. As our model describes how the total 
gametocyte population changes over time, we used the 
relationship for the sex ratio to estimate the male and 
female gametocyte densities, and translated this into an 
infectivity using the published model.24 This procedure is 
described in the online supplementary methods.
survey data for times to obtain treatment
To investigate the potential effect of delay to treatment 
in endemic settings, we used data from cross- sectional 
household surveys in subSaharan Africa in 2016 and 2017 
and in which caregivers were asked to report the time 
taken to obtain antimalarial medication following fevers 
in children under 5 years old.26 Here, we further stratified 
the data by country, fitting a separate log- normal distri-
bution in each case (see online supplementary figure 3 
for the data and distributions). Data from seven coun-
tries were used: Burundi, Ghana, Sierra Leone, Ethiopia, 
Malawi and Uganda.
Patient and public involvement
There was no patient or public involvement in the devel-
opment or execution of this research study.
resulTs
Gametocyte dynamics in untreated and treated infections
Gametocytaemia in untreated infections is determined 
by the fraction of asexual parasites committing to the 
sexual pathway, the maturation time for gametocytes 
and the circulation time of the mature gametocytes (see 
also the Methods section and online supplementary 
methods). The observed inter- individual variation, which 
is very high for all three parameters, is captured by the 
distributions defined in table 1. For example, the mean 
value for the circulation time of mature gametocytes was 
7.7 days while for some patients a circulation time of 
twice this value was required to provide a good model fit. 
The median value for the sexual commitment rate, α , was 
0.011. This is higher than the value found for another 
model that use this dataset32 as we used asexual parasi-
taemia on odd days, rather than daily data, to generate 
the observed gametocyte densities. The mean maturation 
time was found to be 7.6 days (a duration of 1.9 days in 
each immature gametocyte stage). The best- fit model for 
one patient is shown in figure 1.
We next used clinical trial data from Burkina Faso36 to 
characterise the drug action of AL against the sexual stage 
parasites (see the Methods section and online supple-
mentary methods for full details). Asymptomatic chil-
dren with patent gametocytes at screening were treated 
with AL and were followed up to track their gameto-
cyte carriage over the subsequent days. The best- fit PD 
parameters that define Eq. (1) in the Methods section 
are given in table 1, which also specifies which parame-
ters were fitted and which were held fixed. It is important 
to note that the PD model is intimately coupled to the 
PK model and should be viewed in that light. We found 
that the best- fit model required that the artemisinin- 
derivative have some effect against mature gametocytes, 
unlike the model in Gerardin et al38 although this effect 
is much weaker than our model estimate against asexual 
parasites.14
running the model and estimating the infectivity of a malaria 
episode
Our within- host model is summarised in online supple-
mentary figure 4, the caption of which lists the data 
sources used for calibration. In the model, approximately 
5% of perfectly- adherent patients experience parasito-
logical treatment failure, as found in clinical trials (see 
eg Atwine et al39). Panels (B) and (C) of figure 1 shows 
two illustrative simulations: one where AL successfully 
clears the infection, and another where treatment fails 
and the asexual parasitaemia rebounds, leading to 
renewed production of gametocytes. As described in the 
online supplementary methods, we used the gameto-
cyte density to estimate the patients’ infectivity using the 
model due to Bradley et al.24 To quantify a patient’s total 
infectivity over the course of an infection, we calculated 
the area under the infectivity curve (AUIC) (yellow area 
in panels (D) and (E) of figure 1). In the case where 
treatment succeeds, the clearance of the asexual para-
sitaemia prevents further production of gametocytes; 
in this instance the AUIC was 0.08. This means that, if 
the patient was bitten once a day for the duration of the 
infection they would, on average, infect 0.08 mosquitoes. 
The simulation in which treatment fails demonstrates the 
large effect that treatment failure has on the total infec-
tiousness of a malaria infection. Since, in this example, 
the recrudescent infection is not retreated, its total infec-
tivity is comparable to a completely untreated infection 
(in this case the AUIC was 19.4).
These simulations suggest that an important contri-
bution to onward transmission can stem from treatment 
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Table 1 Part A: summary of parameter values describing gametocytaemia in untreated infections, as fitted to 76 malaria 
therapy patients. Best- fit values were obtained for each patient, as described in the Methods section. The distributions stated 
here describe the large variation observed within the group of patients studied. In each case, four distributions were assessed 
for goodness of fit (normal, log- normal, gamma and Weibull distributions). We sample from these distributions to generate 
dynamics in our within- host model. The median value of α is 0.011, while the mean gametocyte maturation time is 7.6 days. 
Part B: best- fit parameters and units for the PD model, describing the rate at which AL kills gametocytes, as defined in Eq. 
(1). Parameter  kji   is the maximum (max.) killing rate for drug  j  against gametocyte stage  Gi . Eq. (1) shows how killing rates 
depend on drug concentration, with killing rates halved at the  C50  concentration of each drug. For both drugs we retain the  C50  
concentrations fitted in a previous publication.14
A. Parameters governing the gametocyte dynamics
Parameter Distribution Description
 α Log- normal distribution  µ = −4.4 ,  σ = 1.9 . 
Distribution truncated at 0.3
Commitment rate of asexual parasites
 1/β Normal distribution,  µ = 1.9 ,  σ = 0.6 . 
Distribution truncated at (1, 3)
Mean time spent in each immature gametocyte stage 
(in days)
 1/β5 Normal distribution,  µ = 7.7 ,  σ = 4.1 . 
Distribution truncated at (1.4,16)
Mean circulation time of mature gametocytes (in 
days)
B. Pharmacodynamic parameters for AL against gametocytes
 
Value for AM (95% 
credible intervals in 
brackets) Value for LMF Fixed or Fitted  
 kj1 
0.18 0.13 Fixed Max. killing rate of stage 1 and 2 
gametocytes (1/hour)
 kj3 
0.11 (0.09–0.12) 0.04 Fitted for AM, fixed 
for LMF
Max. killing rate of stage 3 and 4 
gametocytes (1/hour)
 kj5 
0.08 (0.07–0.10) 0 Fitted for AM, fixed 
for LMF
Max. killing rate of stage 5 (mature) 
gametocytes (1/hour)
 Cj50 
3.3 125 Fitted previously for 
asexual parasites14
Drug concentration (ng/ml) at which killing 
rate is half of its maximum
AL, artemether- lumefantrine; AM, artemether; LMF, lumefantrine.
failure if the recrudescent infection is not retreated. 
This depends on whether symptoms return, as well as 
whether a person seeks a second course of treatment. We 
reviewed nine clinical trials that stratified day 28 PCR- 
corrected failure rates into late clinical failures versus 
late parasitological failures (LPF) that is, the latter have 
no symptoms when parasites recur. Overall, 12 out of 46 
patients (26.0%) were classified as clinical failures.40–48 
This percentage may vary with the level of naturally 
acquired immunity but assessing this was beyond the 
scope of this investigation. Furthermore, the majority of 
studies considered did not have data on the likelihood of 
an LPF progressing to a symptomatic failure after day 28. 
Throughout this study, we varied the proportion of treat-
ment failures that receive a second course of medication, 
to show how this affects the results obtained. In the case 
where a recrudescent infection is retreated, the second 
course of treatment is sought after the patient’s parasi-
taemia exceeds their pyrogenic threshold.
The impact that delayed treatment has on transmission
In the model, the timing of treatment is determined 
by the parasite density at which fever commences (the 
pyrogenic threshold), and the subsequent time taken 
to seek treatment.14 Delaying access to treatment allows 
the build- up of the gametocyte population and, there-
fore, increases the capacity for transmission, even when 
treatment is subsequently successful. We illustrate this 
effect in figure 2, both at the individual and cohort level, 
showing how changing the time to obtain treatment 
affects the size of the gametocyte population. Generating 
a large ensemble of simulations, we show that infections 
treated within 24 hours of the development of symptoms 
are highly unlikely to contribute to transmission (median 
AUIC=0.0019), whereas infections treated after a delay 
of a week are more likely to contribute to transmission 
(median AUIC of 0.27).
To investigate the potential effect of delay to treatment 
in endemic settings, we used data from cross- sectional 
household surveys in sub- Saharan Africa in 2016 and 
2017 and in which caregivers were asked to report the 
time taken to obtain antimalarial medication following 
fevers in children under 5 years old26 In the seven coun-
tries considered, treatment was obtained most promptly 
in Burundi and Sierra Leone, where 72% of patients 
reported receiving treatment either the same or next day 
after fever onset. In Ethiopia, 45% of patients reported 
receiving treatment either the same or next day after 
fever onset, while 20% reported that four or more days 
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Figure 1 Panel (A) displays malaria therapy data for one 
patient, showing asexual (blue line) and sexual (orange 
circles) parasitaemia. the purple curve shows the best- 
fit model for gametocyte density. Based on the patient’s 
asexual parasitaemia, we estimated parameter values 
determining the proportion of parasites committing to 
the sexual pathway, the sequestration time of immature 
gametocytes and the circulation time for mature 
gametocytes. For this patient, the best- fit model had a 
maturation time for gametocytes of 9.8 days (parameter 
 β = 59.1  hours), and a mean circulation time for mature 
gametocytes of 9.2 days (parameter  β5 = 221.3  hours). 
The commitment rate during the first wave of asexual 
parasitaemia was  α1 = 0.021 . Panels (B)–(E) show two 
illustrative model simulations where fully adherent, prompt 
treatment with artemether- lumefantrine either successfully 
clears parasitaemia (panel (B)) or, alternatively, the 
parasitaemia rebounds (panel (C)). The vertical dashed 
line indicates the timing of the first dose of treatment. The 
blue lines in panels (B) and (C) show the density of asexual 
parasites and the red lines show the density of gametocytes. 
Panels (D) and (E) indicate the infectiousness over time of 
the two simulated patients, based on their gametocytaemias. 
Here P(Infection), the probability that a feeding mosquito is 
infected, is calculated on each day of the malaria episode. 
To quantity the total infectiousness of an episode of malaria, 
we calculated the area under the infectivity curve (AUIC), 
the value of which is displayed on the panel. For the case in 
which treatment failed, the patient did not receive a second 
course of antimalarials in this instance.
Figure 2 Simulation results illustrating how increasing 
the time taken to obtain treatment following the onset of 
fever leads to increased infectivity. the upper panel shows 
a simulated infection, with asexual parasite density in blue 
and gametocyte density in red. Seven model runs are 
shown, varying the time at which treatment with artemether- 
lumefantrine starts (vertical, dashed lines) and removing 
variation due to other factors (eg, individual- level variation in 
the PK model, the patient’s pyrogenic threshold, maturation 
and circulation times of the gametocytes, etc). For each 
model run, the area under the infectivity curve (AUIC) was 
calculated. The relation between the AUIC and delay to 
treatment in this instance is shown in the inset. More general 
results are shown in the lower panel, where results were 
obtained from a simulated cohort of 10 000 patients, to 
highlight the individual- level variation in the model. Delay to 
treatment was grouped into 1- day- wide bins. for each bin, 
we summarise the infectivity of the episodes by showing 
the median AUIC (filled circles) and the interquartile range 
(vertical lines). for all results presented here, adherence to 
treatment was perfect.
were required to obtain treatment (compared with only 
2% in Burundi and 1% in Uganda). In figure 3 we show 
how the time to obtain treatment impacts the mean infec-
tivity of a simulated cohort of patients in each country, 
compared with a cohort who receive treatment after 
24 hours, in line with WHO recommended policy.13 With 
the times to treatment reported in Ethiopia, we estimate 
that the mean infectivity of a treated malaria episode is 
1.5 times greater than when treatment is received after 
24 hours, assuming all recrudescent infections were 
retreated. This effect is due to a greater contribution to 
infectivity from the first wave of gametocytaemia, driven 
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Figure 3 Model fits to data describing delay to obtaining antimalarial treatment in seven sub- Saharan African countries, and 
model estimates for how this affects infectivity to mosquitoes. The left panel shows the best- fit log- normal distribution in each 
country for time taken to obtain antimalarial medication after the onset of fever. The raw data for each country is displayed in 
online supplementary figure 3. To determine the timing of the first dose of artemether- lumefantrine in our within- host model, we 
sampled from one of these distributions. The right panel shows how each distribution affects the model- estimated infectivity of 
a treated malaria infection over time, focussing on the first wave of gametocytaemia. For each distribution, we averaged results 
over 10 000 simulations. According to the model and survey data, mean infectivity is lowest when the data collected in Burundi 
and Sierra Leone is used (turquoise and purple, with mean AUICs of 0.52 and 0.53 respectively), and highest for Ethiopia (pink, 
mean AUIC of 0.71). The AUICs shown here pertain to the case where all recrudescent infections are retreated. this panel also 
shows the average infectivity when treatment is obtained 24 hours after the onset of fever, reflecting WHO treatment guidelines 
(grey dashed line, mean AUIC 0.47). AUIC, area under the infectivity curve.
by the proportion of the cohort waiting several days for 
treatment.
The impact that imperfect adherence has on transmission
Poor adherence to a treatment regimen slows the clear-
ance of gametocytes after treatment, as well as increasing 
the probability that treatment fails to clear the asexual 
parasite population. We estimated mean infectivity 
for patients who completed treatment with those who 
missed doses, starting by removing the sixth dose, then 
removing the fifth and sixth dose and so on (figure 4). 
In each case, three scenarios for retreatment were used: 
(i) No patients receive a second course of medication; 
(ii) Patients who fail treatment receive a second course 
of AL with probability 1/3; (iii) All patients who fail treat-
ment receive a second course of AL. For each scenario we 
examine the relative contributions from residual gameto-
cytes post treatment (which all patients will have, regard-
less of whether treatment is successful), and gametocytes 
produced following treatment failure. In the case of 
perfectly- adherent patients, retreating all recrudescent 
infections nearly halves the mean AUIC for the cohort, 
reducing it from 1.32 to 0.67 (figure 4). These results 
indicate that, although only a small percentage (~5%) of 
adherent patients fail treatment, these individuals may 
make relatively large contributions to the mean infec-
tivity of the cohort.
We observe large increases in average infectivity when 
the treatment regimen is not completed (figure 4). For 
example, in the case where no recrudescent infections 
are retreated, our model suggests that patients who 
missed the last dose out of the total of six were 2.2 times 
as infectious as fully- adherent patients, while patients 
who missed the last two doses were 3.8 times as infec-
tious. Although a small part of this effect is due to slower- 
clearance of gametocytes after treatment (under 1%, for 
both patients who took five and four doses), the increases 
in infectivity are driven almost entirely by increased treat-
ment failure rates.
We further estimated the impact of imperfect adher-
ence using individual- level data collected in Tanzania 
in 2012.15 Here, AL was dispensed in Smart Blister 
Packs, which recorded the timing of when each pill was 
removed from the packet in patients who were largely 
unsupervised, except sometimes for the first dose. As 
per Challenger et al14 we used data from 482 patients 
as input for our model, and compared the mean infec-
tivity obtained with those found for perfectly- adherent 
patients, again exploring three retreatment scenarios 
for recrudescent infections. In the case where one- third 
of patients were retreated following treatment failure, 
the observed adherence patterns increased mean infec-
tivity by a factor of 2.2 compared with perfectly- adherent 
patients (figure 4). When no patients were retreated, 
mean infectivity increased by a factor of 2.2, and in the 
case where all patients were retreated mean infectivity 
increased by a factor of 2.4. The variation in these values 
can be explained by noting that the total infectivity of a 
cohort stems from two sources: residual gametocytes that 
circulate following treatment, which are present regard-
less of whether the infection is successfully cleared, and 
gametocytes produced following treatment failure (see 
figure 4). Only the contribution from the latter can be 
reduced by retreating recrudescent infections. There-
fore, the proportion of total infectivity that is due to 
first- wave gametocytes increases when more recrudescent 
infections are treated. Again, the observed increase in 
average infectivity is driven largely by additional treat-
ment failures, although we also observe a small contri-
bution from post treatment gametocytaemia (about 6% 
of the increase in mean infectivity for the cohort that 
received no retreatment).
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Figure 4 Model output showing how failure to complete treatment can increase onwards transmission of the parasite. 
Results for perfectly- adherent patients (six doses) are compared with those for patients who did not take all doses. The bars 
marked ‘five doses’ shows results for patients who took only the first five doses, the bars marked ‘four doses’ shows results 
for patients who took only the first four doses, and so on. We also compare results for perfectly- adherent patients with those 
obtained using data on adherence to artemether- lumefantrine, collected in Tanzania in 2012 (purple bars). In each case, we 
examined three scenarios for retreating recrudescent infections, as indicated for the three lowest bars. In each bar, the lighter 
colour shows infectivity due to treatment failure in the cohort, while the darker shade represents infectivity from gametocytes 
that circulate after treatment. this latter contribution to the mean infectivity (mean AUIC) was 0.19 for the perfectly- adherent 
cohort, compared with 0.23 for the cohort simulated with the adherence data, and 0.43 for the cohort that took only the first 
two doses. For the results generated from the Tanzanian cohort, the mean AUIC was calculated from an ensemble of 1000 
simulations for each of the 482 adherence profiles. In the other scenarios, the mean AUIC was calculated from 10 000 model 
simulations. For comparison, the mean AUIC for a completely untreated cohort was 39.0 (red bar). Hence for perfect drug 
adherence, treated infections were between 29 (no recrudescent infections retreated) and 51 (all recrudescent infections 
retreated) times less infectious than untreated ones. All results shown here used the delay- to- treatment distribution fitted to 
demographic health survey data from all available sub- Saharan African countries, which was used in our previous work.14 
AUIC, area under the infectivity curve.
dIsCussIon
The efficacy of malaria treatment and its impact on 
transmission potential are typically measured under 
controlled conditions, rather than in routine health-
care settings. Here, we estimated that onward trans-
mission from a treated cohort of patients with real-
istic adherence patterns is more than double that of 
perfectly- adherent patients. The major driver of this 
increased transmission in our analysis is treatment 
failure without retreatment, leading to chronic subse-
quent infections of long duration. Imperfect adherence 
also led to slower clearance of gametocytes following 
treatment, regardless of whether the asexual parasites 
were successfully cleared, but this had a relatively small 
impact on transmission potential.
We also looked at how delays in obtaining antimalarials 
following fever affects onward transmission, based on data 
from seven endemic countries. Assuming patients were 
fully- adherent, we found that using these waiting times 
in the model increased patients’ capacity to transmit 
malaria by up to 1.5- fold, compared with patients treated 
after 24 hours. This effect stems from the long maturation 
time of gametocytes in falciparum malaria, and the high 
susceptibility of immature gametocytes to artemisinin 
derivatives. Our analysis quantifies the role that prompt 
and effective treatment has in reducing onward transmis-
sion, and of course it also has a critical role in alleviating 
clinical symptoms and reducing the risk of severe disease 
which we did not quantify here. A limited amount of data 
was available for some countries, such as Ethiopia and 
Malawi, and timing of treatment is self- reported. There-
fore, the data should be interpreted as illustrative of the 
range of current access times, rather than painting a 
detailed picture of access to antimalarials in the countries 
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considered. Furthermore, access to treatment within a 
country is likely to be highly heterogeneous and change 
over time. As more data becomes available, more detailed 
models for this variable can be developed, rather than 
assuming a single distribution for each country.
While timing and adherence are important within 
cohorts of treated patients, our analysis suggests that 
in situations where a significant proportion of infec-
tions remain completely untreated, the contribution 
to transmission from these infections may be much 
greater than contributions from treated infections. 
This has been found to be the case in a number of 
modelling studies.38 49–52 In our model, for example, 
the mean AUIC from an untreated symptomatic cohort 
is 35 times higher than that of a cohort with realistic 
adherence patterns (assuming one third of infections 
are retreated, see figure 4). This is particularly relevant 
considering evidence that in sub- Saharan Africa in 2015 
only 19.7% of symptomatic RDT- positive children under 
5 years old in sub- Saharan Africa received an ACT.10 
Therefore, increasing access to treatment remains a 
priority. Efforts in this direction are being made, both 
to improve affordability of quality- assured ACTs, and 
their availability in remote areas.53 54 Expanding access 
to treatment can be implemented by community- health 
workers, as recently reported in Rwanda.55 This type of 
approach can also reduce the time required to obtain 
treatment, as the need to travel to a health centre is 
removed.
Some published within- host models, largely informed 
by malaria therapy data, contain both asexual and sexual 
parasites, and consider effects of antimalarial drugs on 
both parasite populations.38 50 Our approach is broadly 
similar, although our PD model against gametocytes is 
calibrated against clinical trial data at the level of indi-
vidual patients, rather than at a cohort level. To our 
knowledge, this approach has not been carried out 
before. Furthermore, we believe that the combination 
of a within- host modelling framework with individual- 
level adherence data provides much- needed insight into 
the impact of poor adherence at both the patient and 
population level. It is instructive to compare our esti-
mates for the impact of treatment on infectivity to those 
obtained by Johnston et al.50 In that study, the authors 
explore a range of treatment scenarios and report the 
‘effect size’ of treatment, defined as the fold reduction 
in infectivity due to treatment. Here the authors used 
an infectivity model due to Jeffery and Eyles,56 from a 
study of mosquito feeding on malaria therapy patients. 
For treatment with an ACT, the effect size of treatment 
was estimated to be 87.3, much higher than our range of 
29–51 (see figure 4), and up to 162.1 with the addition 
of primaquine (see table 2 of Johnston et al50). The main 
reason our treatment effect size appears much smaller 
is that treatment is not always successful in our model: 
even when adherence is perfect infectivity from a treated 
cohort is boosted due to the 5% of infections that recru-
desce. The choice of infectivity model also influences 
the numerical results obtained. Johnston et al also used 
a second infectivity model, due to Carter and Graves57 
and based on data from multiple studies, which esti-
mated much smaller effect sizes for treatment (less than 
10). Such different results are obtained because the two 
models generate very different estimates for an individu-
al’s infectivity prior to treatment. We believe that using a 
recently- published infectivity model,24 which quantified 
gametocyte densities using quantitative reverse transcrip-
tase PCR rather than microscopy, enables us to make an 
improved assessment of infectivity, based on an individu-
al’s gametocytaemia.
Although we have only considered treatment with AL 
in this work, the framework outlined here would enable 
similar PD models to be fitted for other ACTs given appro-
priate data. In addition, interventions that are designed 
to target mature gametocytes rather than the asexual 
parasites, such as single low- dose primaquine, could also 
be assessed. To do this, however, the model would need 
to reflect the sterilising effect of some gametocytocidal 
drugs precedes the gametocyte clearance effects.58 59 In 
this work, we have considered all circulating gametocytes 
to be fully viable. A more detailed model, assessing the 
sterilising effects of antimalarial drugs, would be a very 
interesting avenue for further work.
There are several limitations to our analysis. Adher-
ence and treatment- seeking behaviour may vary with age, 
which we have not explored here. There is evidence that 
adults receive more mosquito bites than young children, 
which would influence their relative transmissibility.60 
As discussed in the Methods section and online supple-
mentary methods, more detailed parasitaemia models 
would provide more precise quantitative insight into the 
process of gametocytogenesis. Also, our model of parasi-
taemia in untreated infections is calibrated against data 
from infected individuals with little or no previous expo-
sure to malaria. We do not consider the role of immunity 
acquired by exposure over a longer time period, which 
will reduce the parasite densities of malaria infections, as 
well as reducing the proportion of infections that become 
symptomatic. Therefore, our results are most relevant in 
low- transmission settings, particularly as it is likely that a 
lower proportion of infections go untreated, increasing 
the importance of treatment in reducing transmission. 
It is in precisely these settings where one would hope to 
interrupt transmission using a range of tools, including 
good access to treatment.
Incorporating naturally- acquired immunity into well- 
calibrated within- host malaria models remains a chal-
lenging undertaking, due to the lack of longitudinal data 
from untreated infections. One model used cross- sectional 
data from malaria endemic areas to assess how acquired 
immunity reduces parasite densities in infections.61 
The results presented here will also vary depending on 
the duration of untreated falciparum infections, which 
display large variation between patients,62 and will vary 
with exposure to the parasite.63 64
copyright.
 o
n
 D
ecem
ber 12, 2019 at LSHTM
 Consortia. Protected by
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001856 on 10 December 2019. Downloaded from 
10 Challenger JD, et al. BMJ Global Health 2019;4:e001856. doi:10.1136/bmjgh-2019-001856
BMJ Global Health
ConClusIons
We have used within- host modelling to show how delays 
in obtaining antimalarials and imperfect adherence to 
the dosing regimen can lead to increased transmission of 
the parasite. These effects are not readily measurable in 
clinical trial settings for clear ethical reasons. As well as 
quantifying how delayed treatment and imperfect adher-
ence to the dosing regimen can increase a treated indi-
vidual’s capacity to transmit malaria, our work suggests 
that the major priority should be reaching patients who 
do not currently have access to treatment. The WHO’s 
Global Technical Strategy for Malaria aims to reduce the 
global malaria burden by 90% by 2030,2 and aiming to 
achieve universal access to quality- assured antimalarials is 
one of the key tools in helping to achieve this.
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